New Jersey, USA-based clinical-stage biotech Imunon has appointed Dr Douglas Faller as chief medical officer, effective 18, ...

Boehringer Ingelheim today revealed that the FIBRONEER-ILD trial of nerandomilast met its primary endpoint, which was the ...

The Indian subsidiary of French pharma major Sanofi has received marketing authorization for Rezurock (belumosudil tablets) in India.

In a statement on Friday, the USA’s National Institutes of Health (NIH) said it would cut grants for "indirect costs" related ...

Pliant Therapeutics, a Californian biopharma focused on discovering and developing fibrosis drugs, saw its shares close down ...

France-based biopharma company Medincell this morning revealed it is to receive a $5 million development milestone from ...

The ORPHAN Cures Act (HR 946), a bipartisan bill that removes barriers to treating and curing rare diseases, was reintroduced in the US House of Representative last week.

A new bill has been presented for a pilot scheme that will allow pharmaceutical companies in Denmark to negotiate ...

News last week including US biotechs Alumis and Acelyrin announcing that they are merging to create a late-stage clinical ...

Marking World Cancer Day 2025, this week's Executive Q&A is with Diego Santoro, General Manager & Head of International ...

Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...

Riemser is a pan-European specialty pharma company that has strengths in the marketing and distribution of pharmaceuticals in niche areas of oncology, neurology, infectious diseases and other fields.